Use of phy906 as treatment for inflammatory bowel disease and/or irritable bowel syndrome

Abstract

The present invention includes a method of using PHY906 for treating a bowel disorder including inflammatory bowel disease and irritable bowel syndrome. Particularly, the present invention provides a multiple symptoms treatment for the bowel disorder.

Description

RELATED PATENT AND APPLICATIONS[0001]This application claims benefit to U.S. Provisional Patent Application No. 60 / 982,608, filed on Oct. 25, 2007 and entitled “Use of PHY906 as Treatment for Inflammatory Bowel Disease and / or Irritable Bowel Syndrome”, which is herein incorporated by reference in its entirety.[0002]This application is related to U.S. patent application Ser. No. 09 / 522,055, entitled “Herbal Composition PHY-906 and Its Use in Chemotherapy”, which was filed on Mar. 9, 2000 and abandoned; International Application PCT / US01 / 07353, entitled “Herbal Composition PHY906 and Its Use in Chemotherapy”, which was filed Mar. 8, 2001 and published as WO 2001 / 66123; U.S. Provisional Patent Application No. 60 / 625,943 filed on Nov. 9, 2004 and entitled “Herbal Composition PHY-906 and Its Use in Chemotherapy”; U.S. patent application Ser. No. 11 / 100,433, entitled “Herbal Composition PHY906 and Its Use in Chemotherapy”, which was filed on Apr. 7, 2005 and published as U.S. 2005 / 0196473...

AI Technical Summary

Benefits of technology

[0032]In another embodiment, the present invention provides a method of inhibiting a nuclear factor-kappa B (NF-κB) by contacting the NF-κB with a composition comprising an herbal preparation having Scutellaria, Glycyrrhiza, Ziziphus and Paeonia.

Problems solved by technology

Since the symptoms, course of disease, and prognosis vary from patient to patient, no standard treatment exists for IBD.

It delivers 5-aminosalicylic acid (5-ASA) to the intestine but comes with disagreeable side effects in some patients, such as headache, nausea, loss of appetite, vomiting, rash, fever, and decreased white blood cell count.

Corticosteroids are not effective in preventing flare-ups and therefore are rarely used for maintenance therapy in IBD.

Since long-term use results in side effects, these agents are recommended only for short-term use in order to achieve remission, but they are not used frequently in the latter case.

Generally, antibiotics are not considered useful for those with UC; the exception is toxic megacolon.

The areas of active disease may narrow, forming strictures, which can block the passage of digested food.

IBS in general and IBS-D in particular have a significant negative impact on the quality of life (QOL) for the many people who suffer from this condition; it causes lost days from work and interferes significantly with home-based, social, and leisure activities.

Many studies were not of adequate size and / or were uncontrolled or poorly controlled.

Several clinical studies in China have suggested the potential of TCM herbal formulations in the treatment of IBS, but these have lacked adequate trial design, poor randomization techniques, and / or lack of blinding(33).

Numerous treatments for IBD and IBS have been developed, but most of these treatments do not have desirable efficacy or are single-symptom remedies.

Images